Background and Purpose
Atrophy of the hippocampus is an important clinical diagnostic marker of Alzheimer’s disease (AD), and so assessments of hippocampal activity and its subdivisions might provide invaluable information. This study compared the glucose metabolism of hippocampal subdivisions in mild-AD patients and healthy controls.

Methods
High-resolution T2* -weighted gradient-echo magnetic resonance imaging (MRI) images and 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) images were acquired using 7.0-T MRI and high-resolution research tomograph FDG-PET, respectively, in 9 early-stage AD patients and 10 healthy subjects. The hippocampal body was divided into three equal parts (anterior, middle, and posterior), and in each part a region of interest (ROI) was drawn over the cornus ammonis (CA)1, CA2/3, CA4/dentate gyrus (DG), and subiculum. The standardized uptake values of the hippocampal subdivisions were calculated for each ROI as ratios relative to the pons standardized uptake value. Statistical analysis was conducted using the Mann-Whitney U test.

Results
Patients with early-stage AD patients showed significantly less metabolic activity than healthy controls focally in the middle ($p=0.050$) and posterior ($p=0.034$) CA2/3 regions of the right hippocampus, and significantly less activity throughout the left hippocampal body in the anterior CA2/3 ($p=0.027$) and CA4/DG ($p=0.027$) regions, the middle CA1 region ($p=0.011$), and the posterior CA1 ($p=0.034$), CA2/3 ($p=0.007$), and CA4/DG ($p=0.014$) regions.

Conclusions
It was possible to use high-resolution PET-MRI fusion images to identify hippocampus subdivisions and assess glucose metabolism in the subfields. Reductions in metabolic activity were found to vary along the hippocampal axis in early-stage AD patients.

Key Words
Alzheimer’s disease, hippocampus, hypometabolism, fluorodeoxyglucose.

INTRODUCTION
Memory impairment is the most common and earliest symptoms of Alzheimer’s disease (AD). Atrophy of the mesial temporal lobe—and especially of the hippocampus—as detected in neuroimaging is known to be related to episodic memory impairment, and thus is used as an important marker for the clinical diagnosis of AD. The hippocampus1 is structurally complex and composed of the four parts of the cornus ammonis (CA1–4), the dentate gyrus (DG), and the subiculum. These regions have different structures2-4 as determined by in-vitro and ex-vivo histological methods.¹ The small size of the hippocampus makes it difficult to identify and segment the hippocampal subdivisions in magnetic resonance imaging (MRI). MRI at 3 tesla (T) provides performance that is sufficient for general cases but not for delineating the hippocampal subdivisions, and so studies employing 3-T MRI have fo-
cused on structural and functional changes in the entire hippocampi and other brain regions. However, 7-T MRI provides a higher signal-to-noise ratio and thus a high spatial resolution, which allows better segmentation of the subdivisions of the human hippocampus. For example, volumetric analyses of hippocampal subdivisions in AD patients have revealed significant volume losses in CA1 and the entorhinal cortex, with these losses being correlated with memory performance.

Positron-emission tomography (PET) with ¹⁸F-fluorodeoxyglucose (FDG) is commonly used for clinical imaging in AD and is an important indicator of neuronal injury, but its usefulness is restricted by its relatively low spatial resolution. Recently introduced brain-dedicated, high-resolution research tomograph (HRRT) PET scanners have a spatial resolution of up to 2.5 mm full width at half maximum, but even this is inadequate for identifying important small brain subdivisions. However, Cho et al. combined anatomical information obtained by high-resolution MRI with HRRT-PET images to successfully assess glucose metabolism in the hippocampal subdivisions of healthy subjects.

The present study applied the same combination of high-resolution two-dimensional T2* -weighted gradient-echo MRI and FDG-PET imaging protocols to mild-AD patients and cognitively healthy subjects in order to determine whether these technologies in combination could identify changes in glucose metabolism within the hippocampal subdivisions in AD patients.

METHODS

Participants
This study included 19 participants, comprising 9 early-stage AD patients and 10 healthy control subjects. The AD patients met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for probable AD. The cognitive statuses in both groups were assessed using the Seoul Neuropsychological Screening Battery, which is used as a standardized neuropsychological battery in Korea that includes the Korean version of the Mini Mental State Examination and the digit span test, the Rey Complex Figure Test and Recognition Trial, the Seoul Verbal Learning Test, and the Controlled Oral Word Association Test. Age-matched healthy controls that met the following conditions were included: 1) no history of a neurological or psychiatric disorder, 2) normal cognitive function as determined by neuropsychological tests, and 3) able to perform the normal activities of daily living. The study was approved by the Institutional Review Board of Gil Medical Center, and all participants signed an informed-consent form (IRB No. H-0907-014-038).

Neuroimaging data acquisition
Data were acquired using systematically calibrated HRRT-PET (Siemens, Knoxville, TN, USA) and 7.0-T MRI (Siemens, Erlangen, Germany) scanners as described previously. Forty minutes after the intravenous injection of 185 MBq of FDG, participants underwent a 30-minute HRRT-PET scan and a 6-minute transmission scan for attenuation correction. HRRT-PET images were reconstructed using the three-dimensional ordinary Poisson ordered-subsets expectation-maximization algorithm. The imaging resolution was 1.22×1.22×1.22 mm³. MRI scans were then conducted at 7.0 T using an in-house-manufactured eight-channel radiofrequency transmitter and receiver coil. Two-dimensional T2* -weighted gradient-echo images were obtained using the following parameters: repetition time, 750 ms; echo time, 21 ms; flip angle, 30°; resolution, 0.2×0.2×2.0 mm³; imaging orientation, coronal; and 17 slices. The imaging orientation in the coronal plane was perpendicular to the longitudinal axis of the hippocampal body. Imaging planes were set on the hippocampal body at a uniform distance of 4 mm, which included a 2-mm interplane gap.

Data analysis
This study analyzed only the hippocampal body (i.e., not the head or tail) due to the limitation of the number of slices at the high resolution used. The middle slice of the 17 slices was placed at the middle of the longitudinal axis of the hippocampus. The hippocampal body was divided equally along the longitudinal axis into three divisions: anterior, middle, and posterior (Fig. 1A). The first five slices toward the hippocampal head covered the anterior part, the last five slices toward the hippocampal tail covered the posterior part, and the middle five slices excluding both ends covered the middle part. Regions of interest (ROIs) were drawn in the following hippocampal subfields: CA1, CA2/3, CA4/DG, and subiculum (Fig. 1B). The hippocampal subfields were segmented based on previous described criteria. CA4/DG were drawn as an almost elliptical shape in the middle of the hippocampus. A line crossing CA4/DG from the hippocampal sulcus to the outer edge of the temporal horn was drawn as the reference line. An upward perpendicular line dividing the reference line in half indicated the boundary between CA2/3 and CA1. CA1 extended until meeting the hippocampal sulcus at the edge of CA4/DG. The end of the subiculum was positioned at the most-medial point of the temporal cortex.

To allow comparisons with conventional analyses, ROIs of the entire hippocampal body in each subfield were synthesized from longitudinally segmented ROIs. The FDG uptake values in the hippocampal subdivisions were measured using the corresponding ROIs. Standardized uptake values were calculated as ratios relative to the standardized uptake
value for the pons, and were obtained by manually drawing ROIs in the five sagittal planes. Hippocampus and pons ROIs were drawn manually on 7.0-T MRI images using Vinci software (version 2.54, Max Planck Institute for Neurological Research, Cologne, Germany) by two trained specialists. The intrarater reliability was considered satisfactory when the intraclass correlation coefficient was >0.85, as calculated using SPSS Statistics software (version 21, IBM Corp., Armonk, NY, USA). Group comparisons were performed using the Mann-Whitney U test implemented in SPSS software. An asymptotic two-tailed significance probability of <0.05 was considered statistically significant.

RESULTS

As indicated in Table 1, cognitive functioning was significantly worse in AD patients than in controls. The standardized uptake ratios of the entire hippocampal body revealed that glucose metabolism was significantly lower in the AD group than in the control group in the left CA2/3 (p=0.027) and CA4/DG (p=0.018) (Fig. 2).

The AD group showed significantly lower glucose metabolism in CA2/3 of the middle (p=0.050) and posterior (p=0.034) regions of the right hippocampal body compared to controls. In the left hippocampal body, glucose metabolism was significantly lower in the anterior (p=0.027) and posterior (p=0.007) regions of CA2/3, the anterior (p=0.027) and posterior (p=0.014) regions of CA4/DG, and the middle (p=0.011) and posterior (p=0.034) regions of CA1 in AD patients (Fig. 3).

DISCUSSION

This study measured glucose metabolism in hippocampal subdivisions along the longitudinal axis of the hippocampus using high-resolution FDG-PET and 7.0-T MRI in early-stage AD patients and healthy controls. Until recently, the resolving power of FDG-PET was inadequate for studying changes in the metabolism of glucose in the hippocampal subdivisions of AD patients. However, the high spatial resolution of HRRT-PET and 7.0-T MRI systems has made it possible to segment and assess glucose metabolism in the hippocampal subfields. T2*-weighted MRI at 7.0 T makes it possible to delineate hippocampal substructures with higher definition, making hippocampal segmentation possible.17 In a previous study, we were able to assess glucose metabolism in the hip-
pocampus subdivisions in healthy control subjects using these high-spatial-resolution imaging systems. The present study identified differences in glucose metabolism between cognitively normal subjects and AD patients along the longitudinal axis of the hippocampus body in specific hippocampal subfields. Overall, glucose hypometabolism in the AD group was more dominant in the left than the right hippocampus and more pronounced in the CA2/3 region than in the other hippocampal subdivisions.

In the CA1 region, which is known to be affected during early-stage AD, the glucose metabolism was significantly lower in the middle and posterior body of the left hippocampus in the AD group. The glucose metabolism in the CA2/3 region was significantly lower in the middle and pos-
terior body of the right hippocampus and in the anterior and posterior body of the left hippocampus. In the CA4/DG region, the glucose metabolism in the AD group was significantly lower in the anterior and posterior body of the left hippocampus. It is well established that volume loss of the hippocampus is most frequently observed in the CA1 region in AD patients, although CA2/3, CA4/DG, and the subiculum have been shown to be dominantly affected in several studies of mild cognitive impairment (MCI) and AD. In addition, the higher degree of glucose hypometabolism in the left hippocampus is consistent with the loss of gray matter in the left hemisphere was associated with impaired language function in MCI and AD patients.

A notable feature of our results is that they differ from those of previous studies because our data directly reflect functional changes (i.e., differences in glucose metabolism) rather than structural changes in the hippocampus. There is evidence from several studies that the relation between functional and structural changes is dependent on the level of progression in many diseases, including AD. The present study minimized the effects of hippocampal atrophy and the partial volume effect by using manual segmentation and a point-spread-func-

![Fig. 3. Distribution of glucose metabolism within subfields along longitudinal axis of hippocampus. (A) Representative manually drawn ROIs on 7.0-T MRI images. ROIs were drawn on each slice along the longitudinal axis of the hippocampus bilaterally, and the hippocampus was divided into anterior, middle, and posterior parts. (B) Glucose metabolism in the right hippocampus. (C) Glucose metabolism in the left hippocampus. The asterisks indicate significant differences at $p<0.05$. Data are mean and SD values. AD: Alzheimer's disease, CA: cornus ammonis, DG: dentate gyrus, MRI: magnetic resonance imaging, ROI: region of interest.](image-url)
tion deconvolution algorithm, respectively. Nonetheless, the CA2/3 region could still have been affected by such confounders due to its diminutive size. Furthermore, our analysis was applied to subdivisions of the hippocampal body rather than the entire hippocampi, and the hippocampal head constitutes a major part of CA1; this means that a sizeable part of CA1 was not included in our analysis.

This study was subject to several limitations. First, due to its preliminary nature, the number of subjects was too small to allow clinical conclusions to be drawn. Studies involving larger numbers of subjects are therefore required to confirm our findings. Second, our evaluation was limited by excluding the hippocampal head and tail, which was due to the limitation of the number of slices at the resolution used. Third, the AD patients enrolled were relatively young (mostly younger than 65 years), and hippocampal sparing is common in early-onset AD.\(^\text{26}\) The intergroup differences in glucose metabolism were therefore probably smaller than might have been expected. Nonetheless, despite these limitations, this study has demonstrated that it is possible to observe structural and metabolic changes in the hippocampal subdivisions of AD patients.

In conclusion, high-resolution PET-MRI fusion images enabled the identification of hippocampal subdivisions and assessments of glucose metabolism in the CA1, CA2/3, CA4/DG, and subiculum subfields in healthy control subjects and early-stage AD patients. Our findings suggest that the combination of high-resolution PET and MRI may be a useful tool for early AD detection.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (grant no. NRF-2015R1C1A1A0203768).

REFERENCES

1. Duvernoy HM. The Human Hippocampus: Functional Anatomy. Vascularization and Serial Sections with MRI. 3rd ed. Berlin: Springer-Verlag, 2005.
2. Kerchner GA, Hess CP, Hammond-Rosenbluth KE, Xu D, Rabinovici GD, Kelley DA, et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology 2010;75:1381-1387.
3. Shastri L. A computational model of episodic memory formation in the hippocampal system. Neurocomputing 2001;38:889-897.
4. Langston RF, Stevenson CH, Wilson CL, Saunders I, Wood ER. The role of hippocampal subregions in memory for stimulus associations. Behav Brain Res 2010;215:275-291.
5. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012;8(1 Suppl):S1-S68.
6. Theysohn JM, Kraff O, Maderwald S, Schlammann MU, de Greiff A, Forsting M, et al. The human hippocampus at 7 T— in vivo MRI. Hippocampus 2009;19:1-7.
7. Cho ZH, Han JY, Hwang SI, Kim DS, Kim KN, Kim NB, et al. Quantitative analysis of the hippocampus using images obtained from 7.0 T MRI. Neuroimage 2010;49:2134-2140.
8. Bobinski M, Wegiel J, Winiewski HM, Tarnawski M, Reisberg B, Mlodzik B, et al. Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. Dementia 1995;6:205-210.
9. Kerchner GA, Deutsch GK, Zeineh M, Dougherty RF, Saranathan M, Rutt BK. Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer's disease. Neuroimage 2012;63:194-202.
10. Herholz K, Herscovitch P, Heiss WD. NeuroPET: Positron Emission Tomography in Neuroscience and Clinical Neurology; with 66 Figures and 11 Tables. Berlin: Springer-Verlag, 2004.
11. Lewczuk P, Mroczko B, Fagan A, Korchnuber J. Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. Adv Med Sci 2015;60:76-82.
12. Wieruch K, Schmand M, Casey ME, Baker K, Bao J, Eriksson L, et al. The ECAT HRRT: performance and first clinical application of the new high resolution research tomograph. IEEE Trans Nucl Sci 2002;49:104-110.
13. Cho ZH, Son YD, Kim HK, Kim ST, Lee SY, Chi JG, et al. Substructural hippocampal glucose metabolism observed on PET/MRI. J Nucl Med 2010;51:1545-1548.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
15. Ahn HJ, Chi J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul Neuro-psychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci 2010;25:1071-1076.
16. Cho ZH, Son YD, Kim HK, Kim KN, Oh SH, Han JY, et al. A fusion PET-MRI system with a high-resolution research tomograph-PET and ultra-high field 7.0 T-MRI for the molecular-genetic imaging of the brain. Proteomics 2008;8:1302-1323.
17. Mueller SG, Stables L, Du AT, Schuff N, Truran D, Cashdollar N, et al. Measurement of hippocampal subfields and age-related changes with high resolution MRI at 4T. Neurobiol Aging 2007;28:719-726.
18. Schönheit B, Zarski R, Ohm TG. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 2004;25:697-711.
19. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer’s disease. Brain 2006;129:2867-2873.
20. de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience 2015;309:29-50.
21. Hanseew BJ, Van Leemput K, Kavec M, Gragdel C, Seron X, Ivanoiu A. Mild cognitive impairment: differential atrophy in the hippocampal subfields. AJNR Am J Neuroradiol 2011;32:1658-1661.
22. Lim HK, Hong SC, Jung WS, Ahn KJ, Won WY, Hahn C, et al. Automated hippocampal subfield segmentation in amnestic mild cognitive impairments. Dement Geriatr Cogn Disord 2012;33:327-333.
23. Lim HK, Hong SC, Jung WS, Ahn KJ, Won WY, Hahn C, et al. Automated segmentation of hippocampal subfields in drug-naive patients with Alzheimer disease. AJNR Am J Neuroradiol 2013;34:747-751.
24. Yushkevich PA, Pfui JB, Wang H, Xie L, Ding SL, Gerrije EC, et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortices in mild cogni-
tive impairment. *Hum Brain Mapp* 2015;36:258-287.

25. Derflinger S, Sorg C, Gaser C, Myers N, Arsic M, Kurz A, et al. Grey-matter atrophy in Alzheimer's disease is asymmetric but not lateralized. *J Alzheimers Dis* 2011;25:347-357.

26. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. *Lancet Neurol* 2011;10:785-796.